3B-201
- Generic Name
- 3B-201
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
Phase 1
Completed
- Conditions
- Liver FibrosisPulmonary FibrosisMyocardial Fibrosis
- Interventions
- Procedure: Positron Emission Tomography (PET)
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Thomas Hope
- Target Recruit Count
- 16
- Registration Number
- NCT05180162
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 222
- Registration Number
- NCT04939610
- Locations
- 🇺🇸
Hoag Hospital Irvine, Irvine, California, United States
🇺🇸UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸UCSF Medical Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath